Skip to main
LGND

Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target

Ligand Pharmaceuticals (LGND) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ligand Pharmaceuticals is positioned well for future success due to their strong financial position, diverse portfolio of royalty-generating assets, and focus on sustainability. However, there are potential risks such as failed clinical trials and limited funding that could affect their performance. Despite these risks, the company is expected to perform well and has an Outperform rating from analysts.

Bears say

Ligand Pharmaceuticals is heavily reliant on a few commercial assets for a large portion of its expected growth and faces the risk of competition impacting cash flow from these assets after Year 10. In addition, the company has a high number of partnerships and assets under development, which could lead to a lack of focus and poor investment decisions. Finally, there are potential sustainability concerns regarding human capital management and the company's governance standards, as shown by the CEO's dual role and potential conflicts of interest.

Ligand Pharmaceuticals (LGND) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ligand Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ligand Pharmaceuticals (LGND) Forecast

Analysts have given Ligand Pharmaceuticals (LGND) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Ligand Pharmaceuticals (LGND) has a Strong Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $335.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $335.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ligand Pharmaceuticals (LGND)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.